abp-671
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Oct 17, 2018 (NCT03906006)
Timeline
Indications
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
SLC22A12 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06276556 | Phase 2/Phase 3 (Phase 3) | Apr 22, 2024 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT05818085 | Phase 2/Phase 3 (Phase 3) | Aug 11, 2023 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT04638543 | Phase 2 | Nov 30, 2020 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT04303039 | Phase 1 | Mar 31, 2020 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT04060173 | Phase 1 | Sep 30, 2019 | Celerion, Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT03906006 | Phase 1 | Oct 17, 2018 | Celerion, Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. | For profit | 6 | 6 | 3 | 2018 |
| Celerion | For profit | 2 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1